VOR vs MRNA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
VOR Captures Institutional Edge (2โ2 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vor Biopharma Inc. Common Stock (VOR) driven by superior Growth & Margin, Options & Structure while MRNA counters with relative strength in Valuation, Momentum & Technical. Fundamentally, VOR trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, VOR sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VOR | MRNA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.1B | $80.7B | Larger Scale | MRNA |
| Trailing P/E Ratio Valuation | 0.1x | 23.0x | Lower Multiple | VOR |
| Forward P/E Ratio Valuation | N/M | 23.0x | Lower Multiple | MRNA |
| Revenue Growth (YoY) Growth | +0.0% | +29.2% | Higher Growth | MRNA |
| Operating Margin (TTM) Profitability | 0.0% | -80.8% | Higher Margin | VOR |
| Net Profit Margin Profitability | 0.0% | -110.5% | Higher Margin | VOR |
| Return on Equity (ROE) Capital Efficiency | -125.4% | -34.5% | Higher ROE | MRNA |
| 52-Week Range Position Momentum | 65% ($6โ$26) | 67% ($22โ$281) | Stronger Trend | MRNA |
| Beta / 30D Volatility Risk Regime | 1.61ฮฒ ยท 62% Vol | 2.23ฮฒ ยท 78% Vol | Lower Realized Risk | VOR |
| Unified Institutional Score Composite Signal | 62.7 / 100 (BUY) | 40.3 / 100 (SELL) | Higher Composite | VOR |